According to a new report LAMEA Meningococcal Vaccine Market, published by KBV research, the LAMEA Meningococcal Vaccine Market would witness market growth of 9.5% CAGR during the forecast period (2020-2026).
The Brazil market dominated the LAMEA Menveo Market by Country in 2019, thereby, achieving a market value of $5.8 Million by 2026. The Argentina market would witness a CAGR of 6.9% during (2020 - 2026). Additionally, The UAE market is exhibiting a CAGR of 5.6% during (2020 - 2026).
The Quadrivalent market dominated the Saudi Arabia Meningococcal Vaccine Market by Type in 2019, growing at a CAGR of 9.6 % during the forecast period. The Bivalent market is expected to witness a CAGR of 10% during (2020 - 2026).
The Children (2 years & above) and Adults market dominated the South Africa Meningococcal Vaccine Market by Age Group in 2019, growing at a CAGR of 9.3 % during the forecast period. The Infants (0 to 2 years) market is estimated to grow at a CAGR of 12.3% during (2020 - 2026).
Full Report: https://www.kbvresearch.com/lamea-meningococcal-vaccine-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of GlaxoSmithKline PLC (GSK), Pfizer, Inc., Sanofi S.A., Walvax Biotechnology Co., Ltd., Bio-Manguinhos (Oswaldo Cruz Foundation), Bio-Med Pvt. Ltd., Chongqing Zhifei Biological Products Co., Ltd., Hualan Biological Engineering, Inc., Incepta Pharmaceuticals Ltd. and Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)
By Brand
By Type
By Age Group
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
